Regulatory Approval

Without regulatory approval, your meticulously designed study cannot begin, regardless of scientific merit or clinical need. Companies that navigate approvals efficiently understand the requirements needed before submission, prepare comprehensive documentation, and engage reviewers proactively. Without this, you can waste months in revision cycles or discover important flaws that will necessitate a complete redesign.

Building protocols that satisfy regulatory standards

Regulatory approval begins with protocol quality. Reviewers assess whether your study design generates valid evidence while protecting participant safety. Inadequate protocols invite rejection or extensive revision requests that delay approval by months. Your approach needs to demonstrate scientific thoroughness with clear objectives, appropriate endpoints, justified sample sizes, and valid statistical analysis plans.

Start by specifying primary and secondary endpoints with precise definitions, including calculations that show your sample size clearly detects meaningful differences, and describe your statistical methods for analysing results (including the handling of missing data). Document your study design rationale. Safety monitoring plans require particular attention, so make sure to define the stopping rules for unacceptable adverse events. Specify data safety monitoring board composition and review the frequency. Describe procedures for identifying, documenting, and reporting adverse events. All these elements will demonstrate your commitment to participant safety that ethical review boards demand. ISO 14155 provides the international standard for clinical investigations of medical devices, specifying requirements for protocol content, ethics committee approval, informed consent, monitoring, and reporting.

Regulatory reviewers can identify inadequate protocols within minutes of reading. Vague endpoints, unjustified sample sizes, inadequate safety monitoring, and missing risk analyses all signal inexperience that invites heightened scrutiny.

_{Dr Deborah Ascheim. Chief Medical Officer. National Institute for Health and Care}

Securing ethical review board approval

Institutional Review Boards (IRBs) for human studies and Institutional Animal Care and Use Committees (IACUCs) for animal studies provide independent ethical oversight that protects research participants. IRBs evaluate whether the human study benefits justify the risks, informed consent procedures are adequate, and the participant selection is appropriate. IACUCs assess whether animal use is scientifically justified, the 3Rs principles (replacement, reduction, refinement) are followed, and animal welfare standards are maintained.IRB submissions for human studies will require comprehensive documentation beyond your research plan. Include investigator brochures describing your technology and known risks, and provide consent documents written clearly to explain study procedures, risks, benefits, and alternatives. Submit your recruitment materials to ensure they don't coerce participants. Include data management plans describing how you'll protect participant confidentiality.
Animal studies require IACUC approval to demonstrate compliance with the 3Rs principles of replacement, reduction, and refinement. So, justify why your animal studies are necessary. Explain how you minimised animal numbers while maintaining statistical validity. Describe refinements that will reduce pain or suffering. Document humane endpoints that trigger early euthanasia to prevent unnecessary suffering. Ethical review boards will often request modifications before granting approval, with requests that ask you to clarify consent language, add safety monitoring procedures, or modify procedures that reduce your participant’s burden.

Obtaining regulatory agency clearance

Regulatory agency approval requirements vary by jurisdiction and study risks. High-risk studies that include novel devices or vulnerable populations require more extensive regulatory review than low-risk studies. European clinical investigations under the Medical Device Regulation require notification or approval, depending on device class and study design. Higher-risk studies will need explicit approval, while lower-risk studies can proceed after notification (unless competent authorities object). UK studies under MHRA jurisdiction have pre-submission meetings with regulatory agencies, which prove invaluable for complex studies. These consultations allow discussion of study design and approval pathway before investing in full submissions.

Many founders view regulatory approval as adversarial gatekeeping rather than collaborative problem-solving. Regulators want safe, effective devices to reach patients. Companies that engage regulators early as partners navigate approvals more efficiently.

_{Professor Sir Munir Pirmohamed. NHS Chair of Pharmacogenetics at the University of Liverpool}

Ensuring valid informed consent

Informed consent is the ethical foundation of human research. Participants must understand study purposes, procedures, risks, benefits, and alternatives before agreeing to participate. Consent processes require more than just signature collection. They demand a genuine understanding, which is verified through a participant comprehension assessment.

Informed consent documents need to be comprehensive, written clearly to avoid medical jargon. Make sure to explain the potential risks honestly, including their likelihood and severity. Clarify what benefits participants might receive whilst avoiding therapeutic misconception, where participants confuse research with clinical care. Emphasise their voluntariness and their right to withdraw without penalty. Special populations will require enhanced consent protections. Studies involving children or prisoners will need additional safeguards to ensure consent is valid. Vulnerable population research invites heightened ethical scrutiny requiring strong scientific justification.

Document your consent processes thoroughly. Record who obtained consent, when consent occurred, and what questions participants asked. Plan reconsent procedures if protocol amendments materially change risks after initial enrolment.

Implementing safety reporting systems

Robust safety monitoring and reporting systems demonstrate your commitment to participant protection and ensure compliance with the regulators. These systems need to identify adverse events promptly, assess causality and the severity with accuracy, and report any serious events within regulatory timeframes.

Serious adverse events require immediate reporting to institutional review boards, regulatory agencies, and study sponsors. Definitions of seriousness generally include death, life-threatening conditions, hospitalisation, persistent disability, or congenital anomalies (with 24 to 48 hours of awareness for fatal or life-threatening events). Meanwhile, device deficiencies and malfunctions require separate reporting through device vigilance systems (document any performance issues, even if they don't cause participant harm). These reports will inform regulatory understanding of device behaviour and may trigger design modifications that protect future participants.

Regularity approval workshop

Our approach in helping you gain approval will transform your design studies from documents into active studies, generating the evidence that regulators will trust and clinicians value. You’ll understand how to build procedures that satisfy ISO 14155, prepare comprehensive IRB or IACUC submissions that address ethical concerns proactively, and appropriately obtain regulatory agency clearances through pre-submission engagement. By ensuring valid informed consent through accessible documents and verified comprehension, we’ll help you apply robust safety reporting systems that protect participants and maintain compliance. Navigate these gatekeepers efficiently, and your evidence generation begins.

Waypoint checklist

These are the essentials in securing regulatory and ethical approval for clinical or animal studies:

• Executive summary
• Detailed study designs, stats, and clearly defined endpoints
• IRB/IACUC ethical reviews for human and animal welfare
• Regulatory OK – FDA IDE, CE, or local agency greenlight
• Consent/Welfare patient forms or 3Rs compliance
• Safety reporting with humane endpoint protocols
• Align with ISO 14155 (clinical investigations) and 21 CFR 812 (FDA IDE)